BioSculpture Technology, Inc. establishes Obesity Control Research & Development Division

October 21, 2013

October 21, 2013 – BioSculpture Technology establishes the Obesity Control Research and Development Division.  The Division will consolidate and expand current efforts to develop improved methods and devices for the treatment of obesity, metabolic syndrome, and type 2 Diabetes mellitus.

2/3 of affluent populations are overweight and 1/3 are frankly obese.  43% of Developed World is forecast to be      obese in 10 years.  Obesity related chronic diseases account for 75% of overall healthcare spending.  Those diseases include type 2 Diabetes mellitus, hypertension, heart disease, gastric reflux, sleep apnea, autoimmune diseases and cancer.   Those diseases don’t just shorten lives, they reduce the quality of life.

80% of Type II Diabetics are obese. 1 out of 5 healthcare dollars is spent on Diabetes mellitus. Diabetes is the most frequent cause of kidney failure requiring dialysis and a frequent cause of blindness.

Already embarked on the goal of developing alternative bariatric treatments of obesity, metabolic syndrome and type II Diabetes mellitus, BioSculpture Technology has had three U.S. Patents allowed and has numerous U.S. and foreign Applications pending in this area.  

 

 

Advertisements

BioSculpture Technology, Inc. has an important new patent issue.

January 11, 2013

January 8, 2013 – BioSculpture Technology’s licensed patent portfolio is strengthened by the issuance of U.S. Patent 8,348,929 B2Method of and Apparatus for Treating Abdominal Obesity and Metabolic Syndrome in Human Patients.

2/3 of the U.S. population is overweight and 1/3 is frankly obese.   43% of minorities are overweight today and 43% of the general population isf forecast to be obese in 10 years.  As 80% of obese patients develop type 2 Diabetes mellitus which is the leading cause of renal failure and a frequent cause of blindness, obesity is at the core of America’s burgeoning health care cost crisis.

This patent teaches a method and apparatus for endoscopic removal of visceral fat in a minimally invasive procedure that does not involve cutting into the bowel or leaving behind a foreign body.  As such it has the potential of replacing gastric restrictive surgeries (Lap Band or gastric sleeve procedures) or intestinal bypass procedures (roux-en-Y) with a less invasive procedure less fraught with potential complications and sequelae.  Insulin regulating drugs and hypertensive medication may not be needed as the metabolic syndrome is altered.

Visceral fat is a noxious hormone factory which “latches” the body into an abnormally low metabolic rate, an insulin resistant, hungry condition with inflammatory cytokines promoting heart attacks, strokes, autoimmune diseases and cancers.  Removal of small amounts of visceral fat helps the body return to a higher metabolic rate, have lowered insulin resistance, and the patient be less hungry.  A “multiplier” effect may follow with the loss of 7-10x as much body fat.  And the procedure may be repeated as needed without the risk of creating nutritional cripples.

At the very least this patent paves the way for less invasive alternatives which may supplement current modalities.